• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原位反相高效液相色谱法分析完整抗体药物偶联物。

In-situ Reverse Phased HPLC Analysis of Intact Antibody-Drug Conjugates.

机构信息

Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kawasaki, Kanagawa, 210-8681, Japan.

Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, CA, 92121, United States.

出版信息

Anal Sci. 2021 Aug 10;37(8):1171-1176. doi: 10.2116/analsci.20P424. Epub 2021 Jan 29.

DOI:10.2116/analsci.20P424
PMID:33518587
Abstract

The field of oncology has recently seen an exponential growth in antibody-drug conjugates (ADCs) as a biopharmaceutical class with seven ADCs being launched onto the market in the last ten years. Despite the increase in the industrial research and development of these compounds, their structural complexity and heterogeneity continue to present various challenges regarding their analysis including reaction monitoring. Robust and simple reaction monitoring analysis are in demand in the view of at-line in-process monitoring, and can instill control, confidence and reliability in the ADC manufacturing process. Aiming at providing chromatographic methods for conjugation monitoring, we evaluated herein the potential of utilizing reverse phase HPLC analysis, without sample pretreatment, for characterization of traditional cysteine-based ADCs. This analysis can be used for estimation of drug antibody ratio (DAR), which has shown the same trends and results as other well-established HPLC techniques. This methodology was also applied to three ADCs derived from three different antibodies. Additionally, we analyzed unpurified ADC samples existing in a complex reaction matrix and separated ADC species and payload compounds. This investigation was conducted using three different ADCs based on different payloads. The results described herein indicate the potential application of this RP-HPLC methodology in reaction monitoring studies.

摘要

近年来,抗体药物偶联物(ADC)作为一种生物制药类别,在肿瘤学领域呈指数级增长,在过去十年中已有七种 ADC 上市。尽管这些化合物的工业研发有所增加,但它们的结构复杂性和异质性仍然对其分析提出了各种挑战,包括反应监测。鉴于在线过程监测的需求,对强大且简单的反应监测分析的需求不断增加,这可以为 ADC 制造过程提供控制、信心和可靠性。本研究旨在为缀合监测提供色谱方法,评估了在此无需样品预处理的情况下,反相 HPLC 分析在传统半胱氨酸 ADC 表征中的应用潜力。该分析可用于估计药物抗体比(DAR),其与其他成熟的 HPLC 技术显示出相同的趋势和结果。该方法还应用于三种源自三种不同抗体的 ADC。此外,我们分析了存在于复杂反应基质中的未纯化 ADC 样品,并分离了 ADC 种类和有效载荷化合物。本研究使用三种基于不同有效载荷的不同 ADC 进行。本文所述的结果表明,该反相 HPLC 方法在反应监测研究中具有潜在的应用。

相似文献

1
In-situ Reverse Phased HPLC Analysis of Intact Antibody-Drug Conjugates.原位反相高效液相色谱法分析完整抗体药物偶联物。
Anal Sci. 2021 Aug 10;37(8):1171-1176. doi: 10.2116/analsci.20P424. Epub 2021 Jan 29.
2
Hydrophobic interaction chromatography (HIC) method development and characterization of resolved drug-load variants in site-specifically conjugated pyrrolobenzodiazepine dimer-based antibody drug conjugates (PBD-ADCs).疏水相互作用色谱(HIC)方法开发及定点偶联吡咯苯并二氮䓬二聚体(PBD)抗体药物偶联物(ADCs)中药物载量变异体的表征。
J Pharm Biomed Anal. 2020 Feb 5;179:113027. doi: 10.1016/j.jpba.2019.113027. Epub 2019 Dec 4.
3
Analytical Comparison of Antibody-drug Conjugates Based on Good Manufacturing Practice Strategies.基于良好生产规范策略的抗体药物偶联物的分析比较。
Anal Sci. 2020 Jul 10;36(7):871-875. doi: 10.2116/analsci.19P465. Epub 2020 Apr 24.
4
Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis.利用组织蛋白酶B消化结合反相高压液相色谱分析来测定抗体药物偶联物的药物与抗体比例。
J Chromatogr A. 2017 Jan 20;1481:44-52. doi: 10.1016/j.chroma.2016.12.051. Epub 2016 Dec 19.
5
Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.化学定点偶联法生产的抗体药物偶联物分析方法比较:第一代 AJICAP。
Anal Chem. 2019 Oct 15;91(20):12724-12732. doi: 10.1021/acs.analchem.9b02192. Epub 2019 Sep 3.
6
A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates.一种用于抗体药物偶联物稳定性及小分子相关物质分析的尺寸排阻-反相二维液相色谱方法。
J Chromatogr A. 2015 May 8;1393:81-8. doi: 10.1016/j.chroma.2015.03.027. Epub 2015 Mar 16.
7
Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.采用新方法和超高分辨率质谱法提高抗体药物偶联物的表征水平的实用方法。
MAbs. 2018 Apr;10(3):335-345. doi: 10.1080/19420862.2018.1433973. Epub 2018 Feb 20.
8
[The Characterization of Drug-to-Antibody Ratio and Isoforms of ADCs Using LC and MS Technologies].[使用液相色谱和质谱技术对抗体药物偶联物的药物与抗体比率及异构体进行表征]
Yakugaku Zasshi. 2017;137(5):525-528. doi: 10.1248/yakushi.16-00255-1.
9
Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates.抗体药物偶联物的药物抗体比测定的最新进展。
Chem Pharm Bull (Tokyo). 2021;69(10):976-983. doi: 10.1248/cpb.c21-00258.
10
Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.使用重组FcγIIIa受体-配体亲和柱对由AJICAP第一代技术生产的位点特异性抗体-药物偶联物进行色谱分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jul 1;1177:122753. doi: 10.1016/j.jchromb.2021.122753. Epub 2021 May 19.

引用本文的文献

1
Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.抗体-药物和抗体-纳米颗粒缀合物的合成、表征及作用机制的新趋势
Discov Nano. 2025 Aug 18;20(1):139. doi: 10.1186/s11671-025-04303-w.
2
Current advances in separation chemistry for antibody purification and analysis.抗体纯化与分析的分离化学当前进展
Anal Sci. 2025 May;41(5):653-666. doi: 10.1007/s44211-025-00748-2. Epub 2025 Mar 24.
3
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.

本文引用的文献

1
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology.化学偶联技术制备抗体药物偶联物的工艺开发概述。
Expert Opin Biol Ther. 2021 Jul;21(7):963-975. doi: 10.1080/14712598.2021.1846714. Epub 2020 Dec 1.
2
A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.一种利用疏水相互作用色谱法从AJICAP™第一代生产的位点特异性抗体药物偶联物中获得均一产物的纯化策略。
Antibodies (Basel). 2020 May 18;9(2):16. doi: 10.3390/antib9020016.
3
可切割连接子:提高抗体药物偶联物的稳定性和治疗效果。
J Med Chem. 2024 Oct 24;67(20):18124-18138. doi: 10.1021/acs.jmedchem.4c01251. Epub 2024 Oct 15.
4
Tag-free protein modification by lipoate ligase A: exploring substrate tolerance.无标签蛋白修饰的脂酰基辅酶 A 连接酶 A:探索底物耐受性。
Anal Sci. 2024 Jun;40(6):1111-1119. doi: 10.1007/s44211-024-00534-6. Epub 2024 Mar 19.
5
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation.通过化学位点特异性偶联技术制备的双特异性抗体:AJICAP第二代
ACS Med Chem Lett. 2023 Nov 21;14(12):1767-1773. doi: 10.1021/acsmedchemlett.3c00414. eCollection 2023 Dec 14.
6
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.AJICAP第二代:用于抗体药物偶联物生产的改进型化学位点特异性偶联技术。
Bioconjug Chem. 2023 Mar 9;34(4):728-38. doi: 10.1021/acs.bioconjchem.3c00040.
7
Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates.基于美登素类和奥瑞他汀类抗体药物偶联物的物理特性比较
Explor Target Antitumor Ther. 2021;2(6):576-585. doi: 10.37349/etat.2021.00064. Epub 2021 Dec 31.
Analytical Comparison of Antibody-drug Conjugates Based on Good Manufacturing Practice Strategies.
基于良好生产规范策略的抗体药物偶联物的分析比较。
Anal Sci. 2020 Jul 10;36(7):871-875. doi: 10.2116/analsci.19P465. Epub 2020 Apr 24.
4
Antibody Conjugates-Recent Advances and Future Innovations.抗体偶联物——最新进展与未来创新
Antibodies (Basel). 2020 Jan 8;9(1):2. doi: 10.3390/antib9010002.
5
Good Manufacturing Practice Strategy for Antibody-Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP.使用位点特异性化学偶联法合成抗体药物偶联物的良好生产规范策略:第一代AJICAP
ACS Omega. 2019 Nov 26;4(24):20564-20570. doi: 10.1021/acsomega.9b02419. eCollection 2019 Dec 10.
6
Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.化学定点偶联法生产的抗体药物偶联物分析方法比较:第一代 AJICAP。
Anal Chem. 2019 Oct 15;91(20):12724-12732. doi: 10.1021/acs.analchem.9b02192. Epub 2019 Sep 3.
7
Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.用于癌症治疗的抗体药物偶联物(ADC)架构中的潜在药物。
J Cell Physiol. 2020 Jan;235(1):31-64. doi: 10.1002/jcp.28967. Epub 2019 Jun 18.
8
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.泊洛妥珠单抗联合免疫化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤患者的开放性、非随机、1b-2 期研究。
Lancet Oncol. 2019 Jul;20(7):998-1010. doi: 10.1016/S1470-2045(19)30091-9. Epub 2019 May 14.
9
Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future.抗体药物偶联物的前沿多层次分析和结构表征:现状与未来。
Expert Rev Proteomics. 2019 Apr;16(4):337-362. doi: 10.1080/14789450.2019.1578215. Epub 2019 Feb 18.
10
Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates?疏水作用色谱法是表征定点抗体药物偶联物的最适宜技术吗?
J Chromatogr A. 2019 Feb 8;1586:149-153. doi: 10.1016/j.chroma.2018.12.020. Epub 2018 Dec 11.